548 related articles for article (PubMed ID: 31942585)
21. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes.
Kwon YE; Whang KJ; Park YJ; Kim KH
Bioorg Med Chem; 2003 Apr; 11(8):1669-76. PubMed ID: 12659753
[TBL] [Abstract][Full Text] [Related]
23. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
24. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
25. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
26. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
[TBL] [Abstract][Full Text] [Related]
27. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
28. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
29. Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells.
Wang FY; Tang XM; Wang X; Huang KB; Feng HW; Chen ZF; Liu YN; Liang H
Eur J Med Chem; 2018 Jul; 155():639-650. PubMed ID: 29935437
[TBL] [Abstract][Full Text] [Related]
30. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
31.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Cytotoxicity and Reactivity of a Novel Platinum(IV) Family with DNA-Targeting Naphthalimide Ligands.
Navas F; Mendes F; Santos I; Navarro-Ranninger C; Cabrera S; Quiroga AG
Inorg Chem; 2017 Jun; 56(11):6175-6183. PubMed ID: 28488859
[TBL] [Abstract][Full Text] [Related]
33. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of two platinum(II) complexes with 2-methyl-8-quinolinol derivatives as ligands and study of their antitumor activities.
Qin QP; Wang SL; Tan MX; Liu YC; Meng T; Zou BQ; Liang H
Eur J Med Chem; 2019 Jan; 161():334-342. PubMed ID: 30384040
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
36. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
Qin X; Fang L; Zhao J; Gou S
Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
[TBL] [Abstract][Full Text] [Related]
37. New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities.
Franich AA; Živković MD; Ilić-Tomić T; Đorđević IS; Nikodinović-Runić J; Pavić A; Janjić GV; Rajković S
J Biol Inorg Chem; 2020 May; 25(3):395-409. PubMed ID: 32162071
[TBL] [Abstract][Full Text] [Related]
38. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
39. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
40. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
